Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2882312 | 1.00 | TRPM8 (0.38) | TRPM8TACR1PSEN1PSEN2APH1B | |
| SCHEMBL2711844 | 1.00 | TRPM8 (0.38) | TRPM8TACR1PSEN1PSEN2APH1B | |
| SCHEMBL10059090 | 0.85 | TSHR (0.44) | TACR1MTNR1B | |
| SCHEMBL1037910 | 0.85 | TSHR (0.44) | TACR1MTNR1B | |
| SCHEMBL8196277 | 0.85 | TSHR (0.44) | TACR1MTNR1B | |
| SCHEMBL3580847 | 0.79 | TACR1 (0.44) | TACR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3498597 | 0.75 | NOD2 (0.38) | TACR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2713349 | 0.75 | NOD2 (0.38) | TACR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1709471 | 0.69 | KDM4E (0.40) | KDM4EALDH1A1POLBGAAMAPK1 | |
| SCHEMBL1709470 | 0.68 | KDM4E (0.40) | KDM4EALDH1A1POLBGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420622-B2 | Silylated piperidine derivatives | Merck, Sharp & Dohme, Corp. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8389547-B2 | Piperidines and related compounds for the treatment of Alzheimer's disease | MERCK SHARP & DOHME LLC | 2013-03-05 | — | — | US | disclosed |
| US-20100093665-A1 | SILYLATED PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2010-04-15 | — | — | US | disclosed |
| US-20100048623-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-02-25 | — | — | US | disclosed |
| US-7638629-B2 | Piperidines and related compounds for treatment of alzheimer's disease | Merck Sharp & Dohme Ltd, (GB) | 2009-12-29 | — | — | US | disclosed |
| US-20090186919-A1 | PIPERIDINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| EP-2013171-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER S DISEASE | Merck Sharp & Dohme Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| EP-2007724-A1 | PIPERIDINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | Merck Sharp & Dohme Limited (GB) | 2008-12-31 | — | — | EP | disclosed |
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2008-01-24 | — | — | US | disclosed |
| WO-2007125364-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER’S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007116228-A1 | PIPERIDINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | PSEN1, PSEN2, APP | TRPM8 2324/4885TACR1 380/4885PSEN1 1/4885 |
| US-20100093665-A1 | SILYLATED PIPERIDINE DERIVATIVES | PSEN1, PSEN2, SRM | TRPM8 3487/4885TACR1 32/4885PSEN1 1/4885 |
| US-20090186919-A1 | PIPERIDINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | BACE1, PSEN1, PSEN2 | TRPM8 2239/4885TACR1 1010/4885PSEN1 2/4885 |
| US-20100048623-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, PSEN1, BACE2 | TRPM8 1724/4885TACR1 316/4885PSEN1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.